Vaccines for preventing tick-borne encephalitis

Area of Science:

• Virology
• Immunology
• Public Health

Background:

• Tick-borne encephalitis (TBE) is a severe central nervous system disease caused by a tick-borne virus.
• No specific treatment exists for TBE; vaccination is the sole preventive measure.
• TBE can result in fatal neurological conditions like meningitis and encephalitis.

Purpose of the Study:

• To evaluate the effectiveness and adverse effects of vaccines designed to prevent TBE.
• Assessing TBE vaccine performance in diverse populations.

Main Methods:

• Systematic review of randomized and quasi-randomized controlled trials.
• Searched multiple databases including Cochrane, MEDLINE, and EMBASE up to June 2008.
• Two authors independently assessed trial eligibility, data extraction, and risk of bias.

Main Results:

• Eleven trials involving 8184 participants evaluated three TBE vaccine types (IPVE, FSME-IMMUN, Encepur).
• All tested vaccines demonstrated high seroconversion rates exceeding 87%.
• Common local and systemic adverse effects were reported, but none were severe or life-threatening.

Conclusions:

• TBE vaccines demonstrate strong immunogenicity, indicated by high antibody titre responses.
• The direct correlation between seroconversion and clinical protection against TBE requires further investigation.
• While generally safe with no serious adverse events, the clinical efficacy link needs establishment.